Based on the FY 2010 appropriation, the National Institute on Drug Abuse (NIDA) has established the following funding policy for non-ARRA related projects.
NIDA will continue to support the:
- NIH Pathway to Independence Awards (K99/R00) (http://grants.nih.gov/grants/guide/pa-files/PA-10-063.html) to increase and maintain new and talented NIH-supported independent investigators.
Competing
The FY 2010 average cost of competing grants is allowed to increase by 2% over FY 2009.
Non-Competing Continuations (Type 5)
- All non-competing continuations (modular and non-modular) will be funded at 99% of committed levels, including co-funds. This policy does not apply to F's, T's, K's, SBIR/STTR and R13s. Future commitments will be adjusted accordingly.
- Information regarding the NIH Fiscal Policy for Grant Awards - FY 2010 can be found at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-10-039.html
New and Early Stage Investigators
- NIDA is committed to supporting first-time R01 investigators and Early Stage Investigators (by NIH definition). This means new investigator status will be considered in funding decisions and is one factor in funding grants beyond the normal NIDA payline. For the policy on New and Early Stage Investigators go to http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-013.html.
Ruth L. Kirschstein National Research Service Awards (NRSA)
- NIDA will support a 1% increase at all stipend levels